Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Sep;270(3):434-443.
doi: 10.1097/SLA.0000000000003466.

Trends in Treatment of T1N0 Esophageal Cancer

Tara R Semenkovich  1 , Jessica L Hudson, Melanie Subramanian, Daniel K Mullady, Bryan F Meyers, Varun Puri, Benjamin D Kozower
Affiliations
Comparative Study

Trends in Treatment of T1N0 Esophageal Cancer

Tara R Semenkovich et al. Ann Surg. 2019 Sep.

Abstract

Objective: The purpose of this study was to explore nationwide trends in treatment and outcomes of T1N0 esophageal cancer.

Background: Endoscopic treatment has become an accepted option for early-stage esophageal cancer, but nationwide utilization rates and outcomes are unknown.

Methods: T1N0 esophageal cancers were identified in the National Cancer Database from 2004 to 2014. We assessed trends in treatment; compared endoscopic therapy, esophagectomy, chemoradiation, and no treatment; and performed a subgroup analysis of T1a and T1b patients from 2010 to 2014 (AJCC 7).

Results: A total of 12,383 patients with clinical T1N0 esophageal cancer were analyzed. Over a decade, use of endoscopic therapy increased from 12.7% to 33.6%, whereas chemoradiation and esophagectomy decreased, P < 0.01. The rise in endoscopic treatment of T1a disease from 42.7% to 50.6% was accompanied by a decrease in esophagectomies from 21.7% to 12.8% (P < 0.01). For T1b disease, the rise in endoscopic treatment from 16.9% to 25.1% (P = 0.03) was accompanied by decreases in no treatment and chemoradiation, whereas the rate of esophagectomies remained approximately 50%. Unadjusted median survival was longer for patients undergoing resection: esophagectomy, 98.6 months; endoscopic therapy, 77.7 months; chemoradiation, 17.3 months; no treatment, 8.2 months; P < 0.01. Risk-adjusted Cox modeling showed esophagectomy was associated with improved survival [hazard ratio (HR): 0.85], and chemoradiation (HR: 1.79) and no treatment (HR: 3.57) with decreased survival, compared to endoscopic therapy (P < 0.01).

Conclusions: Use of endoscopic therapy for T1 esophageal cancer has increased significantly: for T1a, as an alternative to esophagectomy; and for T1b, as an alternative to no treatment or chemoradiation. Despite upfront risks, long-term survival is highest for patients who can undergo esophagectomy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Patient selection diagram.
FIGURE 2.
FIGURE 2.
Trends in treatment modality usage for clinical T1N0 esophageal cancer.
FIGURE 3.
FIGURE 3.
Overall survival of clinical T1N0 esophageal cancer patients by treatment group. (A) Entire cohort, (B) T1a subgroup, (C) T1b subgroup.
See this image and copyright information in PMC

References

    1. di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018;154:421–436. - PMC - PubMed
    1. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288. - PubMed
    1. Hu Y, Puri V, Shami VM, et al. Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia. Ann Surg. 2016;263:719–726. - PubMed
    1. Farjah F, Gerdes H, Gibson M, et al. NCCN Guidelines Version 2.2018 Esophageal and Esophagogastric Junction Cancers NCCN Evidence BlocksTM. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal_blocks.pdf. 2018. Accessed October 17, 2018.
    1. Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc. 2018;87 907–931.e9. - PubMed

Publication types

MeSH terms